2.54  0.03 (1.2%)		03-10 16:00
Open: 2.52 High: 2.585 Volume: 1,926,252		Pre. Close: 2.51 Low: 2.495 Market Cap: 382(M)

Short term
Mid term
Targets	6-month :	3.3	1-year :	3.71
Resists	First :	2.83	Second :	3.18
Pivot price	2.65
Supports	First :	2.26	Second :	1.88
MAs	MA(5) :	2.53	MA(20) :	2.63
	MA(100) :	3.3	MA(250) :	3.04
MACD	MACD :	-0.2	Signal :	-0.2
%K %D	K(14,3) :	29.4	D(3) :	30.2
RSI	RSI(14): 43.1
52-week	High :	5.22	Low :	2

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ABSI ] has closed above bottom band by 25.1%. Bollinger Bands are 58.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	2.59 - 2.6	2.6 - 2.61
Low:	2.47 - 2.48	2.48 - 2.49
Close:	2.52 - 2.54	2.54 - 2.56

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Fri, 06 Mar 2026
Absci's Andreas Busch to Retire as Chief Innovation Officer, to Serve as Scientific Advisor - TradingView

Fri, 06 Mar 2026
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Fri, 06 Mar 2026
New Absci medical chief gets option to buy 650,000 company shares - Stock Titan

Thu, 05 Mar 2026
ARK Investment Management LLC Increases Stake in Absci Corporation $ABSI - MarketBeat

Tue, 03 Mar 2026
Absci brings former Vertex leader to drive AI-designed therapeutics pipeline - Stock Titan

Tue, 24 Feb 2026
Absci to Report Business Updates and Fourth Quarter and - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	150 (M)
Held by Insiders	1.2669e+008 (%)
Held by Institutions	13.5 (%)
Shares Short	37,390 (K)
Shares Short P.Month	0 (K)

EPS	-1.055e+008
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-7 %
Return on Assets (ttm)	977.2 %
Return on Equity (ttm)	-30.7 %
Qtrly Rev. Growth	2.81e+006 %
Gross Profit (p.s.)	-36.53
Sales Per Share	-26.15
EBITDA (p.s.)	-3.29718e+007
Qtrly Earnings Growth	-1 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-81 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.1
Price to Cash Flow	3.86

Dividend	0
Forward Dividend	3.943e+007
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.